Spray drying TB vaccines for pulmonary administration

Expert Opinion on Biological Therapy

Volumn 8, Issue 7, 2008, Pages 857-863

  Fourie, P B ^a   Germishuizen, W A ^a   Wong, Y L ^b   Edwards, D A ^b  

^a MRC Building   (South Africa)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Aerosol delivery; BCG; Spray drying; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; CRYOPROTECTIVE AGENT; DNA VACCINE; EXCIPIENT; MEASLES VACCINE;

DNA IMMUNIZATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULARY; DRUG STABILITY; FEASIBILITY STUDY; LUNG TUBERCULOSIS; MYCOBACTERIUM BOVIS; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; BCG VACCINE; CHEMISTRY, PHARMACEUTICAL; DESICCATION; DRUG STABILITY; DRUG STORAGE; HUMANS; PARTICLE SIZE; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS VACCINES; VACCINES;

MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG;

EID: 47549103578     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.7.857     Document Type: Review

References (39)

1. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4(6):469-76 •• A state-of-the-art overview of the rationale for, and current status of, new TB vaccine development.
2. Middlebrook G. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol Rev 1961;25:33-146
3. Rosenthal SR, Mcenery JT, Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J Asthma Res 1968;5(4):309-23
4. Rosenthal SR. Aerosol Vaccination. In: Rosenthal SR, editor, BCG vaccine: tuberculosis-cancer. PSG Publishing Company, Inc. Littleton, Massachusetts; 1980. p. 170-2 • An historical overview of early human studies with aerosolized, inhaled BCG.
5. Chougule MB, Padhi BK, Jinturkar KA, Misra A. Development of dry powder inhalers. Recent Patents Drug Deliv Formulation 2007;1(1):11-21
6. Licalsi C, Christensen T, Bennett JV, et al. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999;17(13-14):1796-803 • This paper describes the possibilities/challenges for delivery of a measles vaccine in mass campaigns.
7. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1(1):67-86
8. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis 2007;87(4):257-66
9. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58(9-10):996-1008 • A detailed description of lung physiology, and the physical property requirements of particles for effective pulmonary delivery.
10. Lombry C, Marteleur A, Arras M, et al. Local and Systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res 2004;21(1):127-35
11. Greenway TE, Eldridge JH, Ludwig G, et al. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine. Vaccine 1998;16(13):1314-23
12. Eyles JE, Williamson ED, Spiers ID, Alpar HO. Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 2000;18(28):3266-71
13. Sabin AB. Immunization against measles by aerosol. Rev Infect Dis 1983;5(3):514-23
14. Waldman RH, Mann JJ, Small PA. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. Jama J Am Med Assoc 1969;207:520-4
15. Wong Y-L, Sampson S, Germishuizen WA, et al. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci USA 2007;104:2591-5 •• A detailed description of the whole cell spray drying process used to formulate BCG into a viable aerosol for pulmonary delivery, and some preliminary results on the stability profile of the spray dried BCG.
16. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868-72 • The first paper, to our knowledge, to describe the use of spray drying for engineering large porous particles - dry powders with the physical properties required for optimal pulmonary delivery.
17. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006;58:1009-29
18. Garcia-Contreras L, Wong Y-L, Muttil P, et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci USA 2008;105(12):4656-60 •• A detailed description of the physical properties of BCG formulations for pulmonary delivery, and of effects on immunogenicity following administration of the pulmonary formulations to guinea pig lung.
19. Lu DM, Hickey AJ. Pulmonary vaccine delivery. Expert Rev Vaccines 2007;6(2):213-26 •• A detailed review of previous and current attempts to formulate vaccines for pulmonary delivery, including a list of possible adjuvants for use in pulmonary formulations.
20. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 2002;4:428-37
21. Irngartinger M, Camuglia V, Damm M, et al. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur J Pharm Biopharm 2004;58(1):7-14
22. Shoyele SA, Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 2006;314(1):1-8 • A description of the various possibilities for manipulating the physical properties of biopharmaceuticals to obtain the physical properties required for optimal pulmonary delivery.
23. Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res 1994;11:12-20
24. Skyler JS. Pulmonary Insulin Delivery - State of the art 2007. Diabetes Technol Ther 2007;9(s1):1-3
25. Lian WC, Hsiao HC, Chou CC. Survival of bifidobacteria after spray-drying. Int J Food Microbiol 2002;74:79-86
26. Murillo M, Gamazo C, Goni MM, et al. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis. Int J Pharm 2002;242(1-2):341-4
27. Maa Y-F, Zhao L, Payne LG, Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application. J Pharm Sci 2003;92:319-32
28. Bivas-Benita M, Van Meijgaarden KE, Franken K, et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004;22(13-14):1609-15
29. Bosquillon C, Preat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 2004:96(2):233-44
30. Li H-Y, Neill H, Innocent R, et al. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J Drug Target 2003;11(7):425-532
31. Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2001;70(3):329-39
32. Codrons V, Vanderbist F, Verbeeck R, et al. Systemic delivery of parathyroid hormone using inhalation dry powder in rats. J Pharm Sci 2003;92:938-50
33. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002;99(19):12001-5
34. Sham JO-H, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;269(2):457-67
35. Alpar HO, Somavarapu S, Atuah KN, Bramwell V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005;57(3):411-30
36. Maa YF, Nguyen PA, Andya JD, et al. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm Res 1998;15:768-75
37. Niven R. Dry powder formulations for inhalation. Adv Drug Deliv Rev 1997;26(Special issue):1-67
38. Pitcairn GR, Lankinen T, Seppala O-P, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patients inspiratory effort. J Aerosol Med 2000;13(2):97-104
39. Everard ML. Inhalation therapy for infants. Adv Drug Deliv Rev 2003;55(7):869-78